These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38294984)

  • 1. Osimertinib with Chemotherapy in EGFR-Mutated NSCLC. Reply.
    Planchard D; Jänne PA; Kobayashi K
    N Engl J Med; 2024 Feb; 390(5):478-479. PubMed ID: 38294984
    [No Abstract]   [Full Text] [Related]  

  • 2. Osimertinib with Chemotherapy in EGFR-Mutated NSCLC.
    van Waalwijk van Doorn-Khosrovani SB; Badrising SK; Burgers S
    N Engl J Med; 2024 Feb; 390(5):478. PubMed ID: 38294983
    [No Abstract]   [Full Text] [Related]  

  • 3. Osimertinib in Stage III
    Leighl NB
    N Engl J Med; 2024 Aug; 391(7):652-654. PubMed ID: 39141858
    [No Abstract]   [Full Text] [Related]  

  • 4. Osimertinib Versus Durvalumab Versus Observation After Chemoradiation in Unresectable EGFR-Mutant NSCLC.
    Zhao B; Yao L; Ma W
    J Thorac Oncol; 2024 May; 19(5):e5-e6. PubMed ID: 38719426
    [No Abstract]   [Full Text] [Related]  

  • 5. Osimertinib in Resected EGFR-Mutated NSCLC. Reply.
    Tsuboi M; Herbst RS; Wu YL
    N Engl J Med; 2023 Oct; 389(14):1342. PubMed ID: 37792623
    [No Abstract]   [Full Text] [Related]  

  • 6. Comment on "Consolidation Osimertinib Versus Durvalumab following Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC".
    Chen CY; Wang GS; Wei JC
    J Thorac Oncol; 2024 May; 19(5):e6-e7. PubMed ID: 38719427
    [No Abstract]   [Full Text] [Related]  

  • 7. Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR+ NSCLC.
    Chen LN; Lee ATM; Nagasaka M; Ou SI
    J Thorac Oncol; 2024 Mar; 19(3):380-384. PubMed ID: 38453326
    [No Abstract]   [Full Text] [Related]  

  • 8.
    Giustini NP; Pritchard CC; Kamat NV; Menon MP
    JCO Precis Oncol; 2024 Jul; 8():e2300215. PubMed ID: 38991179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with uncommon EGFR mutations also benefit from first-line osimertinib.
    Romero D
    Nat Rev Clin Oncol; 2024 Feb; 21(2):84. PubMed ID: 38057403
    [No Abstract]   [Full Text] [Related]  

  • 10. Osimertinib in Resected EGFR-Mutated NSCLC.
    Di Maio M
    N Engl J Med; 2023 Oct; 389(14):1341-1342. PubMed ID: 37792622
    [No Abstract]   [Full Text] [Related]  

  • 11. Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
    Moik F; Riedl JM; Ay C
    Ann Oncol; 2024 Mar; 35(3):327. PubMed ID: 38092622
    [No Abstract]   [Full Text] [Related]  

  • 12. Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
    Tsuboi M; Herbst RS; John T; Kato T; Majem M; Grohé C; Wang J; Goldman JW; Lu S; de Marinis F; Shepherd FA; Lee KH; Le NT; Dechaphunkul A; Kowalski D; Bonanno L; Dómine M; Poole L; Bolanos A; Rukazenkov Y; Wu YL
    Target Oncol; 2024 Mar; 19(2):131-134. PubMed ID: 38466534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired Resistance to Osimertinib in
    Bertoli E; De Carlo E; Del Conte A; Stanzione B; Revelant A; Fassetta K; Spina M; Bearz A
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brief Report: Evaluation of Molecular Profiling Strategies for Neoadjuvant Osimertinib in Stage IIIA EGFR-Mutant NSCLC.
    Lu K; Woodward BD; Boys J; Onaitis M; Husain H
    Clin Lung Cancer; 2024 Jan; 25(1):e58-e61. PubMed ID: 37852849
    [No Abstract]   [Full Text] [Related]  

  • 15. Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC.
    Lim SM; Lee JB; Cho BC
    J Thorac Oncol; 2024 Mar; 19(3):376-379. PubMed ID: 38453325
    [No Abstract]   [Full Text] [Related]  

  • 16. Letter to the Editor regarding 'Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study' by Moik F, Riedl JM, and Ay C.
    Passaro A; Wang J; Shah S; Bauml JM; Campelo RG; Cho BC
    Ann Oncol; 2024 Mar; 35(3):328-329. PubMed ID: 38029840
    [No Abstract]   [Full Text] [Related]  

  • 17. Osimertinib in Patients With Non-Small Cell Lung Cancer and Uncommon EGFR Mutations-Chasing Unicorns?
    Wang VE; Gainor JF
    JAMA Oncol; 2024 Jan; 10(1):52-53. PubMed ID: 37991771
    [No Abstract]   [Full Text] [Related]  

  • 18. L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.
    Bersanelli M; Minari R; Bordi P; Gnetti L; Bozzetti C; Squadrilli A; Lagrasta CA; Bottarelli L; Osipova G; Capelletto E; Mor M; Tiseo M
    J Thorac Oncol; 2016 Oct; 11(10):e121-3. PubMed ID: 27257132
    [No Abstract]   [Full Text] [Related]  

  • 19. Divergent
    Rehman M; Kim C; Reuss JE; Kiedrowski LA; Garg RJ; Liu SV
    JCO Precis Oncol; 2021 Nov; 5():939-942. PubMed ID: 34994624
    [No Abstract]   [Full Text] [Related]  

  • 20. Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC.
    Minari R; Bordi P; La Monica S; Squadrilli A; Leonetti A; Bottarelli L; Azzoni C; Lagrasta CAM; Gnetti L; Campanini N; Petronini PG; Alfieri R; Tiseo M
    J Thorac Oncol; 2018 Jun; 13(6):e89-e91. PubMed ID: 29596911
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.